 MHRA reference: FOI2026/00573

 Dear Jamie Halliday,

 Thank you for your information request, which we received on 26 May. We
 have understood your request to be for the following information:

 Please treat this as a request for information under the Freedom of
 Information Act 2000.

 This request concerns cannabis-based products for medicinal use (CBPMs),
 particularly dried cannabis flower prescribed in private healthcare
 settings.

 I am seeking recorded information about whether any national, regulatory,
 clinical, inspection, safety, licensing or policy guidance exists in
 relation to maximum THC percentage limits for prescribed CBPM flower.

 Please provide the following information.

 1. Recorded guidance on THC percentage limits

 Please provide any recorded guidance, policy, inspection guidance,
 regulatory guidance, internal briefing, position statement or other
 recorded information held by your organisation which refers to:

 a. maximum THC percentage limits for prescribed CBPM flower; b. THC
 percentage thresholds such as 20%, 22%, 25%, 26%, 28%, 30% or similar; c.
 whether prescribers or clinics should restrict patients to a maximum THC
 percentage; d. whether higher-THC CBPM flower requires additional clinical
 justification, approval, review, risk assessment or governance oversight.

 2. Basis for any THC percentage cap or threshold

 If your organisation holds information suggesting that THC percentage caps
 or thresholds are used, recommended, expected or considered good practice,
 please provide recorded information explaining:

 a. the clinical, regulatory or evidential basis for those caps or
 thresholds; b. whether such caps are mandatory, advisory, discretionary,
 or left to prescriber judgement; c. whether any cap differs depending on
 diagnosis, age, psychiatric history, prior cannabis use, tolerance,
 treatment response, dose, route of administration, or risk of
 misuse/diversion.

 3. Private clinic prescribing governance

 Please provide recorded information held by your organisation about how
 private CBPM clinics are expected to justify, review, audit or document
 decisions involving higher-THC flower.

 This includes any recorded information about:

 a. prescribing governance;
 b. multidisciplinary review;
 c. specialist sign-off;
 d. audit requirements;
 e. risk assessments;
 f. patient-specific clinical rationale;
 g. situations where a clinic restricts product strength or THC percentage.

 4. No information held

 If your organisation does not hold any recorded information setting,
 recommending, endorsing or discussing a maximum THC percentage limit for
 prescribed CBPM flower, please confirm this explicitly.

 For clarity, I am not requesting patient-identifiable information,
 individual prescribing records, or information about any specific patient.

 If we have misunderstood or misinterpreted your request, please contact us
 as soon as possible.

 We will deal with your request under the Freedom of Information Act 2000
 (FOIA). The statutory time frame for response is 20 working days; this
 begins on the first working day after receipt, and we will respond by 24th
 June 2026.

 If you need to contact us about this request, please quote the reference
 number above.

 As part of the MHRA ongoing mission to increase transparency we aim to
 publish all responses by the end of the following calendar month. We
 redact names and contact information to protect requestors personal
 information.

 If you have any concerns with your response being published you will need
 to contact this inbox and advice the reasons within 2 weeks of receiving a
 response.

 [1]Transparency and freedom of information releases - GOV.UK (www.gov.uk)

 Yours sincerely

 Customer Experience

 Medicines and Healthcare products Regulatory Agency

 10 South Colonnade, Canary Wharf, London E14 4PU

 Telephone 020 3080 6000

 [2]gov.uk/mhra

 [3]Stay connected

 For information on how the Agency uses your personal data and your data
 protection rights, please see our three centres' Privacy Notices: [4]MHRA,
 [5]CPRD and [6]NIBSC.

 Appeal rights

 If you are dissatisfied with the handling of your request, you have the
 right to ask for an internal review. Internal review requests should be
 submitted within two months of the date you receive this response and
 addressed to: [MHRA request email]

 If you remain dissatisfied with the outcome of the internal review, you
 have the right to apply directly to the Information Commissioner for a
 decision. Please bear in mind that the Information Commissioner will not
 normally review our handling of a request unless the requester has first
 asked us to conduct an internal review.

 The Information Commissioner can be contacted through their online webform
 at:
 [7]https://ico.org.uk/make-a-complaint/foi-and-eir-complaints/foi-and-eir-complaints/

 Or in writing to: Information Commissioner's Office, Wycliffe House, Water
 Lane, Wilmslow, Cheshire, SK9 5AF

References

 Visible links
 1. https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fsearch%2Ftransparency-and-freedom-of-information-releases%3Fparent%3D%252Fhealth-and-social-care%252Fmedicines-medical-devices-blood%26topic%3Dcebc01ee-f70a-4397-a552-622e10b62508&data=05%7C02%7CLou.Lander%40mhra.gov.uk%7C72e5f882056f43ff525f08dc40f84d3a%7Ce527ea5c62584cd2a27f8bd237ec4c26%7C0%7C0%7C638456682427204706%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=CxIIiK%2B9wD828Y3KM3mIIdpZzi4zMpnshYi56uexSNI%3D&reserved=0
 2. https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fgovernment%2Forganisations%2Fmedicines-and-healthcare-products-regulatory-agency&data=05%7C02%7CPhilipa.Brobbey%40mhra.gov.uk%7C2e53c527ca25412c4a9808dc2bbb375d%7Ce527ea5c62584cd2a27f8bd237ec4c26%7C0%7C0%7C638433330277773828%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=fJWP9GavBMshp7kvvtWB2xDJGq5AohSlLcsrvzZ5NPo%3D&reserved=0
 3. https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fgovernment%2Forganisations%2Fmedicines-and-healthcare-products-regulatory-agency%23what-we-do&data=05%7C02%7CPhilipa.Brobbey%40mhra.gov.uk%7C2e53c527ca25412c4a9808dc2bbb375d%7Ce527ea5c62584cd2a27f8bd237ec4c26%7C0%7C0%7C638433330277797976%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=ZElTga8zFyY9mcitlPd9amdmkODxMB0cpIV%2B5YW83wQ%3D&reserved=0
 4. https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fgovernment%2Fpublications%2Fmhra-privacy-notice%2Fmhra-privacy-notice&data=05%7C02%7CPhilipa.Brobbey%40mhra.gov.uk%7C2e53c527ca25412c4a9808dc2bbb375d%7Ce527ea5c62584cd2a27f8bd237ec4c26%7C0%7C0%7C638433330277818354%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=%2FJcF1sRm3w9XvwsBgOJ76PBGUiMr9ePAZWO%2BO%2B%2FurSc%3D&reserved=0
 5. https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.cprd.com%2Ftransparency-information&data=05%7C02%7CPhilipa.Brobbey%40mhra.gov.uk%7C2e53c527ca25412c4a9808dc2bbb375d%7Ce527ea5c62584cd2a27f8bd237ec4c26%7C0%7C0%7C638433330277837320%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=GEvfJ2qczf6896eW52zKCh3Tm2YVqtmlRkgCo0a1Fb4%3D&reserved=0
 6. https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.nibsc.org%2Fabout_us%2Fprivacy_notice.aspx&data=05%7C02%7CPhilipa.Brobbey%40mhra.gov.uk%7C2e53c527ca25412c4a9808dc2bbb375d%7Ce527ea5c62584cd2a27f8bd237ec4c26%7C0%7C0%7C638433330277855908%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=qYERlMN38etici12M8tPax60VoiR8XRghk7rMEqOTCo%3D&reserved=0
 7. file:///tmp/http:/about:blank/


